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ABSTRACT 
Introduction: Celiac disease is a T-cell mediated-inflammatory disorder of the small 
intestine precipitated by gluten ingestion. Gluten can be effectively degraded by Rothia aeria, a 
natural resident oral microbe. Rothia bacteria can potentially be developed as a first probiotic for 
celiac disease. 
Aims: To select the optimal culture conditions for R. aeria enzyme expression in vitro and 
determine the ratio of R. aeria to gluten to achieve digestion within 2 hr incubation. 
Materials and Methods: R. aeria were cultivated in Brain Heart Infusion (BHI) with 
different strength (4%, 20% and 100%), and chemical defined media M9 supplemented with 
different carbon sources (glucose, succinate, glycerol, or casein). The effect of incubation time and 
temperature (28°C and 37°C) on the enzyme expression of the bacteria grown in BHI was also 
assessed. Gliadin degradation was investigated by incubating a fixed gliadin concentration (250 
µg/ml) with different amount of R. aeria cell (OD620 1.0, 0.5, 0.25), and analyzed by SDS-PAGE.  
Results:  The OD620 of 24 hr R. aeria culture in 4%, 20%, and 100% BHI were 0.240, 
0.932, and 2.033, respectively. No bacterial growth was observed in M9 broth +2% glucose, 
succinate, or glycerol, but grew well in M9 broth +2% casein with OD620 19.54.  R. aeria exhibited 
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highest activity when grown in 100% BHI (0.22 AU/min) and lowest in 4% BHI (0.1 AU/min). 
Enzyme activities in M9+2% casein were low (0.035 AU/min), not in proportional to the OD of 
R. aeria culture. The specific enzyme activities of R. aeria in 100% BHI was high in log phase (9 
to 12 hr or 12 to 18 hr), but the yield of total activity was less than that of in stationary phase (20 
to 44 hr). The activity of the cells grown at 37°C was higher than at 28°C. R. aeria suspension 
with an OD620 of 1.0 exhibited rapid degradation of gliadins at 250 ug/ml. 
Conclusions: Full strength BHI broth and 20 to 44 hr cultivation at 37°C are considered 
as optimal cultivation condition to obtain a R. aeria cell culture with high enzyme activity. 
Starvation condition do not enhance enzyme expression.   
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1. INTRODUCTION 
 
1.1. CELIAC DISEASE 
 
1.1.1. Definition 
Celiac disease (CD) is an inherent and widespread autoimmune disorder of the upper small 
intestine (Green and Cellier, 2007) It is triggered by ingested gluten proteins found in wheat, rye, 
and barley in genetically predisposed individuals (Green and Jabri, 2003; Kagnoff, 2005; Sollid, 
2000). 
 
1.1.2. Etiology 
CD is caused by the ingestion of gluten, which are present in wheat, barley, and rye. Gluten 
comprises gliadins and glutenins. Gliadin is the alcohol soluble fraction of gluten and contains 
most of the toxic components. The gluten proteins are proline- and glutamine-rich and are difficult 
to be digested by mammalian digestive enzymes. Undigested gliadin fragments remain after 
incubation with gastric, pancreatic, and intestinal brush-border membrane proteases acting in the 
stomach and the small intestine (Shan et al., 2002).  
In patients with CD, the immune response to gliadin fractions lead to an inflammatory 
reaction, mainly in the upper small intestine, characterized by the infiltration of the epithelium and 
the lamina propria with inflammatory cells. This response is attributed to the innate and the 
adaptive immune systems in the epithelium and in the lamina propria, respectively (Green and 
Cellier, 2007). In the epithelium, gliadin damages the epithelial cell resulting in increased 
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expression of interleukin-15 by enterocytes which activates intraepithelial lymphocytes in turn. 
These lymphocytes become cytotoxic and kill enterocytes.  
After entering of gliadins to the lamina propria, they are deaminated by tissue 
transglutaminase (TG2), leading an increase in their immunogenicity by facilitating a strong 
interaction with HLA class II genes HLA-DQ2 or HLA-DQ8 on the surface of antigen-presenting 
cells such as macrophages, dendritic cells, and B cells (Henderson et al., 2007; Kim et al., 2004; 
Molberg et al., 1998). The adaptive response is mediated by gliadin-reactive CD4+ T-helper 1 
cells in the lamina propria that recognize these negatively charged gliadin peptides presented in 
the HLA context. The T cells produce cytokines (Sollid, 2002), particularly interferon-γ (Nilsen 
EM, 1998), which ultimately results in tissue remodeling and villous atrophy, and crypt 
hyperplasia (Kagnoff, 2005; Mohamed et al., 2006).  
The clinical symptoms of CD vary greatly from different ages. Infants and young children 
generally have diarrhea, abdominal distention, and failure to thrive. Furthermore, vomiting, 
irritability, anorexia, and constipation are also common. The most seen in adults is diarrhea, which 
may be accompanied by abdominal pain. Extraintestinal symptoms such as short figure, neurologic 
symptoms, or anemia are often presented in older children and adults (D'Amico et al., 2005). Less 
common presentations include constipation, weight loss, dermatitis herpetiformis, 
hypoproteinemia, hypocalcemia, and elevated liver enzyme levels (Green, 2005).  
A 33-mer peptide from α2-gliadin contains 6 partly overlapping HLA-DQ2-binding amino 
acid sequences that can be deaminated by TG2. This peptide is considered a celiac “superantigen” 
(Shan et al., 2002). The mechanism of the interaction between the processes in the epithelium and 
in the lamina propria has not been fully elucidated yet. 
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The presence of HLA-DQ2 or HLA-DQ8 proteins, products of two of the HLA genes, on 
antigen presenting cells is necessary for the induction of CD (Sollid and Lie, 2005). However, their 
presence is not sufficient for the development of the disease. Studies in siblings and identical twins 
suggested that the contribution of HLA genes to the genetic component of CD is less than 50% 
(Greco et al., 2002). This implicates other factors, e.g. genetic and/or environmental factors as 
contributors to CD. Some non-HLA genes which may influence susceptibility to the disease have 
been identified, specially CTLA4, Myosin IXB, KIAA1109, TENR, IL2, IL21, RGS1, IL18RAP, 
IL18R1, CCR1, CCR2, CCRL2, CCR3, CCR5, XCR1, IL12A, LPP, TAGAP, and SH2B3 
(Adamovic et al., 2008; Babron et al., 2003; Dema et al., 2009; Djilali-Saiah et al., 1998; Garner 
et al., 2009; Greco et al., 1998; Haimila et al., 2009; Koskinen et al., 2009; Liu et al., 2002; 
McIntire et al., 2008; Monsuur et al., 2005; Naluai et al., 2000; Naluai et al., 2001; Romanos et 
al., 2009; van Belzen et al., 2004; van Heel et al., 2007; Woolley et al., 2002). Family history is 
also a factor to those who have CD (Fasano et al., 2003), also Down syndrome (Shamaly et al., 
2007), Turner’s syndrome (Bettendorf et al., 2006), or type I diabetes (Goh and Banerjee, 2007) 
are associated to them. Environmentally, early exposure of infants to dietary gluten (Norris et al., 
2005), early infection with enteropathic viruses (Stene et al., 2006); (Pavone et al., 2007), or a 
change of the bacterial flora (Collado et al., 2007; Collado et al., 2008; 2009; Zanoni et al., 2006) 
have been identified as contributing factors to CD development in childhood. 
 
1.1.3 Diagnosis of Celiac Disease 
CD is recognized as a relatively common condition that may be diagnosed at any age. The 
diagnosis of it requires both a duodenal biopsy and a positive response to a gluten free diet. The 
biopsy taken by gastroduodenoscopy can detect signs of intraepithelial lymphocytosis, infiltration 
4 
of the lamina propria with T cells and plasma cells, crypt hyperplasia, and villous atrophy (Rostom 
et al., 2006). At least four biopsies should be taken to prove CD because the celiac lesions in small 
intestine could be patchy. Also the serological test is important to detect CD. Obviously the IgG 
and IgA antibodies will disappear from the result of serological test once the gluten free diet is 
applied.  
The histologic grading in CD suggested by Marsh is widely used now. It is classified in to 
five degrees as 0, I, II, III, IV, from normal mucosal architecture to hypoplastic condition. It has 
been suggested to consider clinical signs and serology accompanied with biopsies to detect the CD 
more correctly[EH1] (Marsh, 1992). 
 
1.1.4 Current treatment and therapeutic avenues 
The therapy for CD is a lifelong strict adherence to a gluten-free diet; however, the response 
to therapy is poor in up to 30% of patients (O'Mahony et al., 1996). Thus alternative treatments 
are desired (Sollid and Khosla, 2005; (Di Sabatino and Corazza, 2009). The major objective of 
alternative treatment would be to facilitate the safe ingestion of low amounts of gluten without any 
intestinal inflammation. Several current therapeutic avenues effective in different body locations 
including a) intraluminal therapies, b) transepithelial uptake, c) frustrating the adaptive immune 
response, d) immune modulation and e) induction of tolerance to gluten.[EH2] 
[YC3] 
a) Intraluminal therapies 
The purpose of intraluminal therapies is either to reduce gluten immunogenicity or to 
prevent gluten from contacting intestinal epithelium. 
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 1) Wheat variants: Some wheat strains with lower immunogenicity can be selected from 
existing varieties or can be created by genetic modification. The bread wheat (hexaploid Triticum 
aestivum) is the most widely consumed wheat variety. It is generated by hybridation between 
durum wheat (tetraploid Triticum turgidum) and the diploid Triticum tauschii (Ozkan H, 2001). In 
the duodenal biopsies of CD patients, tetraploid wheat-derived gluten peptides showed lower 
toxicity than the hexaploid wheat gluten fraction. Based on this it can be concluded that durum 
wheat, although not harmless, could be much better tolerated than bread wheat in CD (Auricchio 
et al., 1982). 
2) Genetic modification: The effect of genetic deletion of certain gliadin genes has been 
studied in deletion variants of T. aestivum, lacking one locus containing the gluten genes, by using 
RNA interference methodology. Complete deletion of the α-gliadin locus on chromosome 6 caused 
a decrease in total T-cell stimulatory epitopes also impaired the baking properties whereas deletion 
of γ-gliadins, ω-gliadins, and low molecular weight glutenins on chromosome 1 lowered the 
immune stimulatory capacity without compromising baking properties (Schuppan et al., 2009). 
The genetic modification can also be accomplished by mutagenesis, transgenesis, and genome 
editing. The treatment of wheat with radiation or chemicals leading to mutation is an effective way 
to generate novel genetic diversity and has been used to produce over 300 crop cultivars 
(http://mvgs.iaea.org/Defult.aspx). The identification of the gene sequence level has been checked 
by PCR-based screening, known as TILLING (Targeting Induced Local Lesions in Genomes) 
(McCallum et al., 2000). Mutagenesis and TILLING platforms are widely available for wheat now 
(Slade et al., 2005); (Chen et al., 2012); (Sparla et al., 2014). On the other hand, transgenesis by 
either biolistic or Agrobacterium-mediated systems (Sparks and Jones, 2009; Wu et al., 2009) can 
down regulate endogenous genes or adding novel genes. Moreover, genome editing is a new 
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technology in which highly specific changes are made to genomes without leaving any foreign 
DNA.  
 3) Pretreatment of flours: Another approach to eliminate gluten from the dough is by 
fermentation with certain lactobacilli (“sourdough” lactobacilli) that can digest the 
proline/glutamine-rich gluten peptides and thereby reduce immunotoxicity (De Angelis et al., 
2006; Di Cagno et al., 2002; Rizzello et al., 2007).  
Yet another approach is to treat the whole wheat flour with a low-molecular-weight microbial TG 
derived from Streptomyces moboraensis to crosslink glutamines residues thereby preventing their 
deamination in the lamina propria (Yokoyama et al., 2004). 
 4) Neutralizing gluten antibodies [EH4][YC5] : Because orally ingested IgG is highly 
resistant to gastric acidity and remains about 50% active in neutralizing capacity when reaching 
the small intestine and is easy and cheap to produce, this gluten-neutralizing antibody is a very 
attractive approach to eliminate gluten toxic peptides (Warny et al., 1999). Moreover, IgG is 
considered a safe nutritional products similar to milk, thus would not be subject to strict regulatory 
approval. 
 
b) Transepithelial uptake 
The increase of intestinal permeability via opening of the epithelial tight junctions is 
considered an important contributor to the entering of gluten peptides to the subepithelial lamina 
propria. Vibrio cholera secretes the ZOT toxin which opens the intestinal epithelial tight junctions 
by binding to the 66-kDa ZOT receptor (Lu et al., 2000; Uzzau et al., 2001). It has been 
demonstrated that human release a similar paracrine protein called zonulin which acts like ZOT, 
and that zonulin expression is increased in CD. Thus, an octapeptide (AT-1001) was developed to 
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block the ZOT/zonulin receptor thus preventing the gluten-induced “leaky-gut” (Paterson et al., 
2007).  
 
c) Frustrating the adaptive immune response 
TG2 inhibitors that target TG2 cross-linking activity that is the basis of toxic gluten 
modification have been developed (Choi et al., 2005; Lai et al., 1998; Siegel and Khosla, 2007; 
Watts et al., 2005). There are three groups of TG2 inhibitors, they are (1) competitive inhibitors 
(putrescine, spermidine, histamine, monodansyl cadaverin, cadaverine, 5-pentylamine, 
fluoresceine, cystamine, and cysteamine) (Jeitner et al., 2005), (2) reversible inhibitors (guanosine 
triphosphate analogues) (Pardin et al., 2008), and (3) irreversible inhibitors (iodoacetamide, 3-
halo-4,5-dihydroisoxazoles, carbobenzyloxy-L-glutaminyl glycine derivatives, 6-diazo-5-oxo-
norleucine, 2-[(2-oxopropyl)thio] imidazolium derivatives) (de Macedo et al., 2002; Hausch et al., 
2003). The potential ability of TG2 inhibitor treatment is attractive while also considered risky 
because of the widespread tissue distribution of TG enzymes. TG2 inhibitors with a high affinity 
thiol binding group were recently developed which display 70- to 225-fold specificity for TG2 
over TG1, TG3, TG6, and factor XIII, raising the hopes for increasing safety of its utilization 
(Pasternack, Hils, Zedira Company, Darmstadt, Germany, personal communication, September 
2009).         
 
d) Immune modulation 
An innate immune inhibitor decapeptide (QQPQDAVQPF) was isolated from durum 
wheat and tested in various in vitro systems (De Vincenzi et al., 1995; De Vincenzi et al., 1996; 
De Vincenzi et al., 1997; De Vincenzi et al., 1998; Giovannini et al., 2000; Silano et al., 2007a; 
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Silano et al., 2007b; Silano et al., 2008). The researchers hypothesized that the decapeptide induced 
a switch from a Th1 to a Th2 T cell phenotype after down-regulating IFN-γ and up-regulating IL-
10 production in intestinal T cells in CD patients (Silano et al., 2008). Some researchers examined 
modifications of the toxic gliadin peptides to therefore obtain antagonistic peptides (Anderson et 
al., 2006; Biagi et al., 1999; Kapoerchan et al., 2008; Xia et al., 2006). Modification of the proline 
residues P38, P39, and P42 of alpha-gliadin p31-43 can abolish immunogenicity [EH6][Office7] 
(Schuppan 2009).  
 
e) Induction of tolerance to gluten 
HLA-DQ2 has a high affinity to gliadin peptides, is the association followed by the 
activation of CD4+ T cells. To block this process, several peptides also with high affinity to HLA-
DQ2 were designed by amino acid substitutions, dimerization, or introduction of aldehyde groups. 
Modification of α-2-gliadin p57-73 results in partial agonists which significantly inhibit IFN-γ 
production (Anderson et al., 2006). Moreover, replacement of leucine L11 and L18 residues in the 
α-gliadin 33-mer with sterically bulky groups keeps high DQ2 affinity but decrease the T-cell 
recognition (Xia et al., 2006). Also application of azidoproline-containing gluten peptides that can 
block the effect of a stimulatory α9-gliadin peptide when used at high concentration (Kapoerchan 
et al., 2008). 
Adding Bifidobacterium strains to down-regulate the pro-inflammatory [EH8][YC9]effect in 
CD patients is considered a simple and safe method (Medina et al., 2008). Bifidobacterium found 
significantly lower in fecal samples of active CD children also lower in biopsies when compared 
to control subjects (Nadal et al., 2007). Specific strains have been investigated for their anti-
inflammatory and regulatory properties by inducing IL-10 production and regulating the Th1/Th2 
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balance (Baba et al., 2008; Medina et al., 2007). Medina et al. found that B. longum ES1 and B. 
bifidum ES2 could suppress the Th1 pro-inflammatory characteristic of the CD.  
Another approach is the utilization of some parasites. Human or non-human intestinal 
parasites such as helminths Trichuris trichura and Trichuris suis can protect animals from 
developing immune-mediated diseases such as colitis, reactive airway disease, encephalitis, and 
diabetes. Clinical trials show that the administration of helminthes can reduce disease activity in 
patients with ulcerative colitis or Crohn’s disease (Elliott et al., 2007; Summers et al., 2005a; 
Summers et al., 2005b). The rationale of these approaches is that the increased prevalence of 
autoimmune disorders in developed countries is closely paralleled by absence of intestinal 
parasites (Sollid and Khosla, 2011).  
 
1.2 Gluten degrading enzymes 
The use of nonhuman proteases for gluten detoxification was conducted in the late 1950s 
(Krainick and Mohn, 1959). Recently two types of enzyme are appealing to treat CD via oral 
therapy by cleaving large peptides. One is a proline-specific endopeptidase PEP (prolyl 
endopeptidase) (Hausch et al., 2002; Marti et al., 2005; Piper et al., 2004; Pyle et al., 2005; Shan 
et al., 2002) and the other one is a glutamin-specific cysteine protease EP-B2. 
 
1.2.1. Prolyl endopeptidases (PEP) 
It has been shown in many researches that PEP can cleave proline-rich gluten peptides. 
After cleavage, two shorter peptides were generated including a new amino and a carboxyl 
terminus. They could be further digested by brush-border aminopeptidases and carboxypeptidases 
at the intestinal surface, thus the immunotoxic property from gluten was eliminated. PEP can be 
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produced from different bacterial strains. Dariusz et al. (2006) investigated the newly discovered 
PEP from fungi Aspergillus niger (AN-PEP) (Edens et al., 2005). AN-PEP is a member of the 
serine peptidase family S28 and shares more sequence homology with lysosomal Pro-X 
carboxypeptidase and dipeptidyl peptidase II than with prolyl oligopeptidases. It has a good 
property that it works optimally at 4-5 pH, and remains stable at pH 2, which is resistant to the low 
pH condition in human stomach. Also this AN-PEP is completely resistant to gastric pepsin. 
Therefore it can arrive the small intestine successfully to degrade the T cell stimulatory peptide as 
well as intact gluten molecules. Matthew Siegel et al. (Siegel et al., 2006) compared the two 
promising PEPs from Flavobacterium meningosepticum (FM) and Myxococcus xanthus (MX). 
They found that FM-PEP showed a general improvement over MX-PEP especially in targeting the 
immunodominant α2 epitope. 
Prolyl endopeptidase (PEP) expressed in various microorganisms such as Flavobacterium 
meningosepticum, Sphingomonas capsulatae, Myxococcus xanthus, and Aspergillus niger which 
can cleave the immunotoxic large gliadin peptides like the 33-mer (Cornell et al., 2005; Marti et 
al., 2005; Mitea et al., 2008; Pyle et al., 2005; Stepniak et al., 2006). However, the effectiveness 
of PEP is restricted on the length of their substrates (Fulop et al., 2000; Shan et al., 2004), the long 
time consuming to completely hydrolyze the gliadin peptides, and their best activity at near neutral 
pH (Cerf-Bensussan et al., 2007; Matysiak-Budnik et al., 2005). PEP from Aspergillus niger is 
active at low pH (~pH 2), has a higher activity than that from F. meningosepticum, thus is favorable 
to be applied to cleave peptidase-resistant gliadins during gastric transport (Mitea et al., 2008; 
Stepniak et al., 2006). Furthermore, the combination of PEP from S. capsulatawith or A. niger and 
the barley-derived enzyme endoprotease B2 can effectively digest whole wheat gluten in vitro and 
in vivo (Gass et al., 2006; Gass et al., 2007). 
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1.2.2. Endoprotease B2 (EP-B2) 
EP-B2 is secreted as a proenzyme (proEP-B2) into the acidic endosperm of germinating 
barley seeds, where it is autoactivated quickly to its mature form in conditions that are similar to 
that found in the stomach (Jacobsen and Varner, 1967; Koehler and Ho, 1990; Mikkonen et al., 
1996). Mature EP-B2 is stable and active over a wide pH range and efficiently digests α2-gliadin 
which is known for its immunotoxicity (Bethune et al., 2006).  
  
1.2.3. PEP and EP-B2 mixture (ALV003) 
A potential concern was that PEP would not be able to detoxify gluten rapid enough in the 
duodenum (Koning and Vader, 2003; Matysiak-Budnik et al., 2005), and the effectiveness of PEP 
might be limited by its substrate chain length restrictions. It was considered that the PEP can be 
enhanced by the administration of EP-B2 (Bethune et al., 2006). According to Siegel (Siegel et al., 
2006), at a gluten: EP-B2: FM-PEP weight ratio 75:3:1, grocery store gluten is fully detoxified 
within 10 min of stimulated duodenal conditions, as judged by chromatographic analysis, biopsy-
derived T cell proliferation assays, and a commercial anti-gluten antibody test. Therefore this 
combination of PEP and EP-B2 could be a suitable oral therapy of CD. A mixture of both enzymes 
has reached clinical trials and is produced by Alvine Pharmaceuticals as ALV003. 
 
1.3 Gluten-degrading resident bacteria 
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1.3.1. Non oral gluten-degrading resident bacteria 
In the past few years, a new source of gluten-degrading enzymes has been explores, namely 
the bacteria naturally colonizing the human digestive tract, starting in the oral cavity (Caminero et 
al., 2014; Helmerhorst et al., 2010; Zamakhchari et al., 2011) had isolated 144 strains belonging 
to 35 bacterial species that could be involved in gluten hydrolysis in the human intestine. They 
found that most of the strains were classified within the phylum Firmicutis, mainly from the genera 
Lactobacillus, Streptococcus, Staphyloccus and Clostridium. Some of the isolates were classified 
within the phylum Actinobacteria, mostly from the genus Bifidobacterium. Only 12% of the 
isolates were gram negative bacteria from the phylum Proteobacteria. Moreover, they found that 
several bacterial strains belonging to 11 bacterial species have the ability to hydrolyze the 33-mer 
peptide. Some bacteria, such as Lactobacillus mucosae, L. rhamnosus, and Clostridium 
botulinum/sporogenes have a higher hydrolyzing activity than other bacteria like Enterococcus 
faecalis or Bacillus licheniformis, even the latters can partly hydrolyze the 33-mer.   
Recently, many sourdough lactic acid bacteria were tested for proteolytic activity (Di 
Cagno et al., 2002) and some lactobacilli was selected and used for further studies. They had 
specialized peptidases ability to digest pro-rich peptides, including 33-mer. 
VSL#3 (VSL Pharmaceuticals, Gaithesburg, MD) is a highly concentrated (ca. 5 x 1011 cells/g) 
mixture of lactic acid and bifido-bacteria which has been discovered to colonize the intestine and 
to promote several beneficial effects for the host (Campieri and Gionchetti, 1999; Gionchetti et al., 
2000; Kaur et al., 2002). From De Angelis et al. (De Angelis et al., 2006), they found that 109 
cells/g of VSL#3 could hydrolyze totally the 33-mer epitope (750 ppm) after 24 hr of incubation 
at 37oC. A considerable amount (150 ppm) of 33-mer was hydrolyzed after 4 hr of treatment by 
VSL#3. It was indicated that the gliadins treated with VSL#3 decreased the activation of the 
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zonulin release, cytoskeleton reorganization, and intestinal permeability compared to non-
hydrolyzed gliadins. Also, they found that the gliadins remained after treatment of VSL#3 had 
very low or absent toxicity.  However, the hydrolyzing ability was lost when individual strains 
which composed of it were tested, indicating that no single strain contains the total portfolio of 
peptidases required to degrade pro-rich polypeptides. The utilization of VSL#3 during food 
processing to produce pre-digested and tolerated gliadins could be promising.  
Gallo (Gallo et al., 2005) purified partially an X-prolyl dipeptidyl aminopeptidase (PepX) 
from sourdough lactobacillus sanfranciscensis and combined it with general aminopeptidase type 
N, and found the 33-mer peptide (0.2 mM) was completely hydrolyzed after 24 hr of incubation at 
30oC. 
Recently, Wei et al. (Wei et al., 2015) isolated and identified some gluten-degrading and 
aciduric microorganisms from human feces, and all the 43 strains are belonged to one species, 
Pseudomonas aeruginosa. P. aeruginosa is a gram negative bacteria and a member of the 
proteobacteria representing <10% of the gut colonizers, of which 90% are bacteroidetes and 
firmicutes species (Turnbaugh et al., 2007). The enzyme from P. aeruginosa was isolated 
representing pseudolysin, or lasB, which is active in gel at pH 2.0. It shows a remarkable ability 
to cleave major immunogenic gluten peptides, such as 33-mer, at pH 4.0 and 7.0, but not at pH 2.0 
and 3.0. Enzyme combination from various origins with the specificity from pseudolysin could 
effectively cleave immunogenic peptides at low pH conditions.  
 
1.3.2. Oral gluten-degrading resident bacteria 
Helmerhorst et al. (Helmerhorst et al., 2010) first reported the evidence for gluten-
degrading microorganisms inhabiting the upper gasto-intestinal tract. They found the gliadin, 33-
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mer, and 26-mer peptide were proteolytically degraded at a wide pH range (pH 3-10). The results 
indicated that the oral microorganisms are a viable source of novel enzymes. Fernandez-Feo et al. 
(Fernandez-Feo et al., 2013) isolated human saliva and plague and found some oral microbial 
species which can cleave immunogenic gluten and/or gluten derived substrates including Rothia 
mucilaginosa, Rothia aeria, Actinocyces odontolyticus, Streptococcus mitis, Streptococcus sp., 
Neisseria mucosa, Capnocytophaga sputigen, and they present activities at neutral or near-neutral 
pH. Among all these bacterial strains, Rothia mucilaginosa and Rothia aeria were found to rapidly 
hydrolyze the para-nitroanilide-derivitized substrates Z-YPQ-pNA and Z-KPQ-pNA, which are 
the gluten-based substrates. R. mucilaginosa and R. aeria belong to the Rothia genus under the 
Actinobacteria phyla. They are mainly colonizing the oral cavity (Dewhirst et al., 2010); (Yamane, 
2010), R. mucilaginosa, however, has also been found in the upper respiratory tract and the 
duodenum (Ou et al., 2009). R. mucilaginosa and R. aeria were found to degrade gliadin in 
solution. Approximately 50% of the added gliadin amount (250 µg/ml) was degraded in ~30 min. 
Rapid degradation of the 33-mer and 26-mer by R. aeria was noted over 2 hr time interval. Also, 
the R. aeria showed good activity at a wide range of pH from 4 to 10. At pH 3, R. aeria still showed 
activity, although weaker than at pH 7 (Zamakhchari et al., 2011)  At pH 2, no activity from R. 
aeria was noted and the activity could not be reactivated upon transfer to neutral pH values. Tian 
et al. (Tian et al., 2014) investigated the natural microbial inhabitant of the oral cavity, R. 
mucilaginosa, the potential capability to hydrolyze the gliadin 33-mer and 26-mer peptides. They 
found that the incubation of gliadins with R. mucilaginosa cells reduced R5 antibody binding by 
20, 82, and 97% after 30 min, 2 hr, and 5 hr, respectively, at pH 7. Although the elimination of 
epitopes in the 33-mer was less effective than in the 26-mer, the mass spectrometer showed that 
R. mucilaginosa hydrolyzed all the three major immunogenic epitopes comprised in the 33-mer. 
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1.4. Rothia aeria 
R. aeria was first isolated from the air in the Russian space laboratory Mir in 1997 and the 
taxonomic status was investigated by 16S rDNA sequences in 2004 (Li et al., 2004). This gram 
positive strain grows well under aerobic conditions on BHI agar plate. The cells appear coccoid, 
cocco-bacillary or filamentous. Young colonies are white and smooth; mature colonies are rough 
and dry and adhere to the agar medium. R. aeria showed the following common biochemical 
characteristics with Rothia dentocariosa and Rothia mucilaginosa: positive for nitrate reduction, 
pyrazinamidase, alanine-phenylalanine-proline arylamidase, α-glucosidase and β-glucosidase 
activities, hydrolysis of aesculin and acid production from glucose, maltose and sucrose; negative 
for β-glucuronidase, β-galactosidase, N-acetyl-β-glucosaminidase and urease activities and 
production of acid from ribose, xylose, mannitol, lactose and glycogen. The exploitation of R. 
aeria is attractive because it belongs to the normal flora in oral cavity where the entrance of the 
digestive system is and can be a novel source for therapeutic gluten degrading enzymes.  
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2. AIMS OF STUDY[gw10][Office11] 
 
Celiac disease is a T-cell mediated-inflammatory disorder of the small intestine 
precipitated by gluten ingestion. Gluten can be effectively degraded by R. aeria, a natural resident 
oral microbe. In order to develop R. aeria as a first probiotic for celiac disease, it is of significance 
to investigate the efficacy of detoxify gluten in vivo. As an initial step, we investigated the optimal 
conditions to obtain high yield of gluten degrading activity.   
Specific aims of this study: 
1. To test the effect of strength and carbon source of bacterial growth media as well as 
incubation time and temperature on the gluten-degrading enzyme expression of R. aeria in 
vitro. 
1. To determine the ratio of R. aeria to gluten that required to achieve digestion within 1 hr 
to 2 hr, the residence time of foods in the stomach/upper intestines. 
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3. MATERIALS AND METHODS 
 
3.1. Growth of Rothia aeria in different conditions 
 
a) Broth strength: R. aeria was cultured from a glycerol stock on Brucella agar plates 
(Brucella with vitamin H & K, A30, Hardy Diagnostics, CA, USA) and incubated at 37oC for 
24-48 hr.  
BHI broth (100%) was prepared by adding 18.5g of BHI powder (BBLTM Brain Heart 
Infusion, BD) to 500 ml of MilliQ water in a 1000 ml flask. After autoclaving for 45 min and 
cooling, several colonies of R. aeria were transferred from the plate with the sterile inoculation 
loop into the bottle. Different BHI broth strengths (20% and 4%) were prepared to compare the 
effect of it on enzyme activity. The total incubation was 24 hr at 370C, and the enzyme activity of 
each bottle was measured every 10 min for 3 hr. The enzyme activity was measured by cleavage 
of suc-AAPF-pNA. 
b) Carbon sources: A chemical defined media M9 broth was prepared by adding 5.64 g 
of M9 minimal salts (Sigma, MO, USA) to 500 ml of MilliQ water in 4 1000 ml flasks. 2% of 
glucose, succinate, glycerol, and casein were added into each flask, respectively. After autoclaving 
for 45 min and cooling, several colonies of R. aeria were transferred from the plate with the sterile 
inoculation loop into these 4 bottles. Bottles of M9+2% glucose, M9+2% succinate, M9+2% 
glycerol were incubated for 7 days. The bottle of M9+2% casein was incubated for 24 hr. All the 
bottles were incubated at 370C. The enzyme activity of each bottle was measured every 10 min for 
3 hr by cleavage of suc-AAPF-pNA. 
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c) Temperature: BHI broth (20%) was prepared by adding 3.7g of BHI powder (BBLTM 
Brain Heart Infusion, BD) to 500 ml of MilliQ water in a 1000 ml flask. After autoclaving for 45 
min and cooling, several colonies of R. aeria were transferred from the plate with the sterile 
inoculation loop into 2 bottles. One bottle was incubated at 370C and the other was at 280C for 96 
hr, and the enzyme activity of each bottle was measured every 10 min for 2 hr. The enzyme activity 
was measured by cleavage of suc-AAPF-pNA. 
d) Incubation time: To determine the generation time (doubling time), aliquots (around 
2.5 ml) of   each R. aeria culture were transferred to two bottles (250 ml/each) of fresh 100% BHI 
to get the same initial OD. Aliquots (1 ml) of the culture were taken at time points from 0-48 hr 
with 2 hr intervals, and the bacterial optical density at wavelength 620nm (OD620nm) were 
determined with a spectrophotometer (Genios Plus, Phoenix). The number of CFU/ml was 
determined as described below in Section 4. The bacterial generation time was calculated with a 
formula: G (generation time) = t (minutes or hours) / 3.3 log b/B (number of generations), where 
b = the concentration of bacteria (or CFU/ml) at the end of the selected time interval and B = the 
concentration of bacteria (or CFU/ml) at the beginning of the time interval 
(http://textbookofbacteriology.net/growth_3.html). The interval chosen for these calculations was 
6-12 hr in experiment 1 and 12-18 hr in experiment 2[EH12][Office13]. 
 
3.2. Enzyme activity Assay 
R. aeria cells harvested from the BHI culture or the Brucella agar plate were suspended in 
PBS (pH 7.0) and adjusted to an OD620 0.6. Aliquots of 200 µl from the suspensions were added 
in triplicate to a 96-well flat bottom microtiter plate (Costar 3596, Corning, NY, USA) containing 
4 µl of 10 mM para-nitroanilide-derivatized enzyme substrates Suc-AAPF-pNA (final 
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concentration 200µM). This substrate is measuring subtilisin enzyme activity, the main enzyme 
produced by the Rothia bacteria (Wei et al., 2015). Controls were suspensions without added 
substrate.  Substrate hydrolysis was monitored by detecting the change in absorbance at 405 nm 
for 3 hr[EH14][Office15] every 10 min at 37oC using a spectrophotometer. 
 
3.3. Rothia aeria batch cultivation 
Rothia aeria was cultured from a glycerol stock on Brucella agar plates (Brucella with 
vitamin H & K, A30, Hardy Diagnostics, CA, USA) and incubated at 37oC for 24-48 hr.  
BHI broth (100%) was prepared by adding 9.25g of BHI powder (BBLTM Brain Heart 
Infusion, BD) to 250 ml of MilliQ water in a 500 ml flask. After autoclaving for 45 min and 
cooling, several colonies of R. aeria were transferred from the plate with the sterile inoculation 
loop into 2 bottles (250 ml/each).  
After incubation shaking (120 rpm) on a platform shaking machine (3D Rocker, model 
130, Denville Scientific INC, USA) at 37oC for 24 to 48 hr. The R. aeria culture was verified to 
be pure by plating on Brucella agar and visual inspection of colony morphology. To obtain certain 
amount of R. aeria cells, the cells were cultured in BHI under the same conditions in 2-liter bottles 
and were harvested by centrifugation for 30 min at 4oC, 17000 g (9700 rpm), using a rotor F10-
6x500y and a Sorvall RC-6 PLUS Superspeed Centrifuge machine (Thermo Scientific, USA). 
After centrifugation, the supernatant was removed and cells were washed twice with sterile PBS. 
After the second wash, the cells were re-suspended in 50 ml PBS and the OD620 was adjusted to 
be around 50, stored in -800C. 
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3.4. Viability of R. aeria batch cultures 
R. aeria cells were suspended in PBS at around OD620= 50. A 10 fold serial dilution series[EH16][Office17] 
was prepared in 1 ml Eppendorf tubes as 10-1, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7, 10-8 dilutions in 
duplicate. Aliquots of 50 µl of each of the suspensions from 10-3 through 10-8 were plated onto 
Brucella agar plates. After incubation at 37oC for 24-48 hr, images were taken using the scanner 
(G: BOX, SYNGENE, Cambridge, UK), and colonies were counted using the GeneTools software 
(SYNGENE, Cambridge, UK).   
 
3.5. Lyophilization of cells 
R. aeria suspensions from the batch cultures cultured for 16, 24, and 66 hr yield typically 
per 2-3 L culture a suspension of 50 ml with an OD620=50. The suspension was aliquoted into 1, 
2, or 3 ml aliquots in 2 ml Eppendorf tubes [gw18][Office19]and centrifuged (Eppendorf 5424, 
Hamburg, Germany) at 21,130 x g (15,000 rpm) for 5 min. The supernatant was removed and cells 
in pellet were dried using a Speedvac. In subsequent experiments, the suspensions were not 
aliquoted, but the about 50 ml in the 50 ml tube was directly centrifuged, the supernatant removed 
and the pellet dried in a lyophilizer (FM 25 EL, Virtis, NY, USA). All dried cell pellets were stored 
in a -80oC freezer.  
 
3.6. Gliadin hydrolysis in gel (gliadin zymography) 
Bacterial cells of R. aeria were harvested from Brucella agar plate or BHI broth after 
incubation at 37oC for 48 hr and suspended in PBS solution at pH 7.0 with OD620 5.0. Aliquots of 
150 µl were centrifuged at 21,130 x g (15,000 rpm) using an Eppendorf centrifuge for 5 min and 
the cells were re-suspended in equal 25 µl of 2x Zymogram sample buffer containing 0.125M Tris-
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HCl, 20% glycerol, 20% SDS, and 0.005% bromophenol blue to each sample. The sample was 
loaded onto a 6% gliadin zymogram gel as described (Fernandez-Feo, 2013) and electrophoresis 
was performed at a constant voltage of 100V in the 4oC in the cold room for around 2 hr. The gels 
were re-natured with 100 ml of renaturing buffer (Invitrogen Novex Zymogram) for 30 min, which 
was repeated once; then washed with developing buffer for 20 min (Invitrogen Novex Zymogram) 
for 2 times. After incubation in developing buffer at 37oC for 48 hr, the gel was stained overnight 
with staining solution containing 0.1% Coomassie blue, 40% methanol and 10% acetic acid. To 
visualize protein bands, the gel was de-stained with the solution of 40% methanol and 10% acetic 
acid. The gels were scanned using a scanner (G: BOX, SYNGENE, Cambridge, UK). 
 
3.7. Gliadin hydrolysis in solution 
Gliadin solution (5 mg/ml) was prepared by dissolving 5 mg of gliadin (Sigma #G3375-
25G) in 1 ml of 60% ethanol and shaking at room temperature for 30 min. Bacterial suspension 
was prepared by suspending R. aeria cells in saliva ion buffer (SIB) to OD620=1.0 or specific 
indication. The experiment was performed in 3 groups: gliadins incubated with R. aeria, as a test 
group; the gliadin only or the bacterium only as controls. All the samples were incubated at 37oC 
and aliquots of 100 µl of each sample were taken at the time points of 0 hr, 0.5 hr, 1 hr, 2 hr, and 
4 hr, and boiled at 100oC for 10 min to stop the enzyme reaction. The samples were lyophilized 
with SpeedVac machine (SpeedVac Plus SC110 A, Savant, NY, USA) for analysis by SDS-PAGE. 
The lyophilized samples were re-suspended with 24 µl MilliQ water and 8µl of 4x Bis-Tris 
w/DDT sample buffer. After boiling for 5 min, the samples were loaded onto a NuPAGE 4-12% 
Bis-Tris gel (Invitrogen, Novex). A 5 µl of aliquot of a protein standard (ProteinTM All Blue 
Standards, BIO-RAD, USA) was loaded to the first lane as the molecular weight markers. 
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Electrophoresis was performed at a constant voltage of 120 V for about 1 hr at room temperature. 
The gel was stained with 0.1% Coomassie blue stain in 40% methanol and 10% acetic acid 
overnight and de-stained with the same solution without dye.  
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4. RESULTS 
 
4.1. Effect of different conditions on bacterial growth 
The OD620 of 24 hr R. aeria culture in 4%, 20%, and 100% BHI were 0.240, 0.932, and 
2.033, respectively.  No bacterial growth was observed in M9 broth +2% glucose, succinate, or 
glycerol but grew well in M9 broth +2% casein with OD620 19.54.  
 
4.2. Growth curve and generation time of Rothia aeria  
The growth curves obtained in experiment 1 and experiment 2 are shown in[EH20][Office21] 
Figures 1A and 1B, resp. The bacteria grew slow at the early stage (0-6 hr for experiment 1 and 0-
12 hr for experiment 2). The OD increased from 0.1341 to 6.098 during the 6-28 hr interval in 
experiment 1 (Fig 1A), and from 0.2226 to 3.36575 during the 12-24 hr interval in experiment 2 
(Fig 1B), representing the logarithmic phase. After 24-28 hr the bacterial growth reached a stable 
level with OD 5.5 – 6.0 (Exp.1), representation the stationary phase or 2.6-3.6 (Exp.2). The 
logarithmic plots of time against the log of the CFU/ml are shown in Figure 1C (Exp.1) and D 
(Exp.2). The log phase, read from the linear plots was occurring from[EH22][Office23] 6 hr to 12 hr 
in Exp.1 and from 12 hr to 18 hr in Exp.2. The generation time (doubling time) of R. aeria was 
1.79 hr (6/ 3.3 x 1.0134=1.7941) or 2.15 hrs (6/ 3.3 x 0.8442= 2.1537) for Exp.1 or Exp.2, 
respectively. 
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[gw24]
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[Office25][gw26][Office27] 
4.3. Bacterial enzyme expression 
Broth strength: R. aeria cultured in BHI broth strength 4%, 20%, and 100% exhibited 
significant different enzyme activity expression (Figure 2A). The enzyme activity in proportional 
to the strength of BHI. 100% BHI showed the highest and 4% BHI the lowest with initial enzyme 
reaction rates 0.22 and 0.1 AU/min, respectively, 20% BHI was in between with the rate 
0.12AU/min (Figure 2B).  
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As shown in Figure 3, the enzyme activities in M9+2% casein were low (0.035 AU/min), 
which is not in proportional to the OD of R. aeria culture.   
 
Figure 3. The effect of carbon sources on R. aeria enzyme activities monitored by cleavage 
of suc-AAPF-pNA. A: enzyme reaction plot in each condition; B: the initial enzyme reaction 
rate derived from the enzyme reaction plot. 
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R. aeria showed higher activity after cultivated in 100% BHI at 37°C than at 28°C as 
shown in Figure 4A. The initial enzyme reaction rate was 0.11 AU/min at 370C, and 0.07 
AU/min at 280C as shown in Figure 4B. 
 
  
 
Figure 4. The effect of incubation temperature on R. aeria enzyme activities monitored by 
cleavage of suc-AAPF-pNA. A: enzyme reaction plot in each condition; B: the initial enzyme 
reaction rate derived from the enzyme reaction plot. 
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[gw28][gw29][Office30]4.4. Enzyme activity of R. aeria throughout the growth phase  
To assess the initial enzyme activity at different incubation time, two experiments were 
performed by incubating R. aeria in two bottles (1 L/bottle) of 100% BHI. The enzyme activity 
was higher in log phase than stationary phase in both experiments (Figure 5A and 5B)  with  the 
average rates 0.3 AU/min at 12 hr of experiment A, or 0.75 AU/min, at 14 hr of experiment B 
(Figures 5C and 5D[EH31])[Office32]. 
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4.5. Enzyme activity and culture OD as a function of cultivation time 
From the same experiments, we also plotted the enzyme activity and culture OD as a 
function of cultivation time (Figure 6A, experiment 1; 6B, experiment 2). As shown in Figure 6A, 
the enzyme activity reached to the highest in 12 hr which referred to the log phase and stayed in a 
stable level in stationary phase. As shown in Figure 6B, the enzyme activity reached to the highest 
in 14 hr which also referred to the log phase and decrease to a lower level in the stationary phase. 
From both experiments, the maximum enzyme activity reached earlier (log phase) than bacterial 
cells as expressed.[gw33][Office34] 
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4.6. The total activity yields as a function of growth 
In order to get sufficient amount of enzyme from R. aeria cells for further experiments, the 
total activity the enzyme yielded from the bacterial culture in terms of OD620nm was assessed. As 
shown in Table 1 and Figure 7, in experiment 2, culture at the time of 20-44 hr (stationary phase), 
with OD unit 2.5-3.5, the total activities yielded by R. aeria were higher from 1.38-1.48; while at 
time 12-18 hr (log phase), with OD unit 0.19-1.5, the total activities were lower from 0.14 to 1.04. 
[gw35][Office36]The total activities reached the highest starting at 32 hr, suggesting stationary phase 
was appropriate time to get higher yield of activity.  
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[gw37][Office38]In the meantime, the enzyme activities of 30 batches (Table 2) corresponding 
cultures were also analyzed. As shown in Figure 8, the enzyme activities of the 16 and 24 hr 
cultures were comparable with the average initial enzyme reaction rates (SD) as 0.121 (0.044) and 
0.118 (0.019) AU/min, and were higher than that of 66 hr as 0.077 (0.027) AU/min, indicating 
early culture (log phase) expressed higher activity than the stationary phase. 
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[gw39]
 
 
4.7. Gliadin Zymography 
The purpose of this experiment was to validate the gliadin degradation activity of R. aeria 
by gliadin zymography. As shown in Figure 9, the gliadin conjugated in 6% zymogram gel was 
hydrolyzed, appeared as white bands in the gel at ~75kDa, by the bacterial cells from both Brucella 
[gw40][Office41]agar plate (Figure 9, lane 2 and 3), and 100% BHI broth (Figure 9, lane 4 and 5).  
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4.8. Gliadin hydrolysis in solution 
The capability of gliadin degraded by R. aeria was also assessed in solution. Mixed gliadin 
(250 µl/ml) with R. aeria of OD6201.0 was incubated for different time points: 0, 0.5, 1, 2, and 4 
37 
hours. Aliquots of 100 µl were centrifuged, and cells were re-suspended in 8 µl 4x sample buffer. 
After electrophoresis, gels were stained with Coomassie blue to visualize proteins with enzymatic 
activity. As shown the major gliadin band at 37 kDa (arrow) in Figure 10, the gliadins were 
degraded by R. aeria in a time-dependent manner after incubation from 0 to 4 hr, with high 
degradation when incubated 2 and 4 hr.[gw42]  In corresponding to the degradation, the degraded 
peptide products at 10 kDa appeared in the same way. Similar gliadin hydrolysis was also 
demonstrated in solution by batches #4, #5, #8, #9, #10, #13, #14, and #15 (Table 2) of R. aeria 
cultures (Figure 11), although there were some varies in the degradation efficiency between the 
different batches.  
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4.9. Effect of cell density on gliadin degradation 
From this experiment, different gliadin to OD ratios were examined in order to decide 
which ratio should be applied appropriately to future in vivo test. A fixed concentration 250 µg/ml 
of mixed gliadins was incubated with R. aeria at OD620 at 1.0, 0.5, or 0.25 at 37
oC for 0.5 and 1 
hr. The degradation was monitored by SDS-PAGE and major gliadin bands at ~37kDa were 
assessed. As show in Figure 12, the gliadins were obviously degraded by R. aeria at OD=1.0 in 1 
hr, while no such degradation were observed by R. aeria at OD=0.5 and 0.25. Therefore, the 
optimal ratio of cell density to gliadin was considered to be 1:250 (OD: µg/ml). [gw43] 
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The information including the amount of viable bacterial cells and activities of 30 batches 
of R. aeria culture were summarized in Table 2. The OD ranged from 78.8 to 5003 with medium 
1143. The viability ranged from 4.0 x 108 to 7 x 1010 CFU with medium 9.25 x 109 CFU. The 
enzyme activity from 0.2004 to 1.2186 OD405/hr with medium 0.5511 AU. All 30 batches will be 
used for the future in vivo and in vitro experiments. 
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[gw44][Office45] 
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5. DISCUSSION 
 
Several media can be applied to culture R. aeria, and the enzyme expression can be 
different cultured from them. One is the Brucella agar plate (Brucella with vitamin H & K, A30, 
Hardy Diagnostics) with Hemin and vitamin K. It is modification of the formulation given by the 
American Society of Microbiology. This medium is rich in nutrients and is a non-inhibitory general 
growth medium for all gram positive and gram negative anaerobic bacteria. The incorporation of 
Hemin and vitamin K into Brucella agar plate enhances the cultivation of some species of 
anaerobes. The media contains dextrose which provides an energy source; peptones to provide 
nitrogenous compounds; and yeast extract to supply vitamin B. Sheep blood provides growth 
factors required by some anaerobic bacteria. In this study, we used Brucella agar plate as nutrient-
rich medium to obtain the inoculum of R. aeria. 
Other selections of cultivating media are from brain heart infusion (BHI), such as BHI agar 
and BHI broth. They may have different effects on enzyme expression. Brain Heart Infusion agar 
(Becton Dickinson and Company) is a general purpose culture medium which supports the growth 
of a wide variety of bacterial and fungal species including many types of pathogens. The main 
ingredients are brain heart infusion, peptic digest of animal tissue, pancreatic digest of casein, 
sodium chloride, dextrose, disodium phosphate, and agar. The standard preparation is to suspend 
52 g of the powder in 1000 ml MilliQ water and mix thoroughly. Heat with frequent agitation and 
boil 1 min to completely dissolve the powder. The final pH is 7.4. The other BHI medium is Brain 
Heart Infusion (BBLTM Brain Heart Infusion, BD) broth. It is an enriched non-selective general 
purpose broth medium that is useful in the cultivation of a wide variety of bacterial and fungal 
species. The basal medium is an infusion from brain and beef heart, with peptic digest of animal 
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tissue, sodium chloride, dextrose, pancreatic digest of gelatin, and disodium phosphate. The 100% 
BHI broth was prepared by mixing 37 g of BHI powder with 1000 ml of MilliQ water. In our pilot 
study, we compared enzyme activities of R. aeria cultured in both of these media and no significant 
difference was noted (data not shown).  
According to prior researches, enzyme was higher in starvation condition by using low 
strength (20%) diluted broth compared to full strength broth. However, in our study, we found the 
enzyme expression in 100% BHI broth was higher than that from 20% or 4% broth. It appeared 
starvation did not enhance the enzyme expression activity by R. aeria and high nutritional supply 
was required. Based on the result of bacterial culture (Figure 7), the most total activity yields 
occurred in the stationary phase which indicting the best harvesting timing of R. aeria even though 
the most enzyme activity occurred in the log phase. 
In general, the more cells the more enzyme produce. In this study, the total bacterial 
enzyme was in proportional to the yield the bacterial cells when R. aeria grew in BHI broth.  
However, it was not observed when the bacterial grew in M9 + 2% casein broth.  
M9 mineral medium is a chemical defined medium used to grow B. subtilis in the presence 
of glucose or other variable carbon sources. It contains Na2HPO4, KH2PO4, NaCl, glucose, MgSO4, 
CaCl2, biotin, thiamin, and trace elements. Casein is a family of related phosphoproteins, 
containing a high number of proline residues. It is the most protein found in milk and 
relatively hydrophobic. In this study, R. aeria grew well in M9 + 2% casein medium in 24 hr but 
showed lower enzyme activity compared to other BHI combinations. This indicates that casein 
provides the nutrition which is needed by R. aeria but does not facilitate high enzyme activity. 
Therefore, BHI was chosen to be the main cultivating medium because it is the most effective 
medium to culture the most of bacteria. Recently, Tsuzukibashi (Tsuzukibashi et al., 2017) 
46 
developed a novel elective medium (ORSM) for isolating oral Rothia species. ORSM consists of 
tryptone, sodium gluconate, Lab-Lemco powder, sodium fluoride, neutral acriflavin, lincomycin, 
colistin, and agar. The average growth recovery of oral Rothia species on ORSM was 96.7% 
compared with that on BHI-Y agar. ORSM appears to be better for R. aeria growth, but it would 
be interest to further study the enzyme expression with this medium.   
Para-nitroanilide-derivatized enzyme substrates Suc-AAPF-pNA (200 µM) is a substrate 
for alpha-chymotrypsin and fungal chymotrypsin-like serine protease. Enzymatic cleavage of 4-
nitroanilide substrates yields 4-nitroaniline which shows yellow color and the changing is 
monitored by detecting the change in absorbance over time at 405 nm. Similar to Tyr-Pro-Gln 
(YPQ) and Leu-Pro-Tyr (LPY), Suc-AAPF-pNA can also be hydrolyzed by gliadin degrading 
enzyme (subtilisins) from Rothia mucilaginosa (Wei et al., 2016). Suc-AAPF-pNA is 
commercially available, more economic and sensitive than YPQ and LPY.  In this study, we 
selected Suc-AAPF-pNA as a substrate to assess the hydrolysis of gliadin immune epitopes. In the 
enzyme assay, it is important to the standardized bacterial amount to assess the enzyme expression 
by certain amount of bacterial cells. In the enzyme assay, R. aeria concentration was standardized 
as OD620=0.6, 50% less than the bacterial cells when used YPQ or LPY as substrate.  
In agreement with the results of AAPF cleavage activity, the activity of gliadin hydrolysis 
in gel and in solution was also detected, indicating that R. aeria grown under our conditions was 
effective in degrading gliadin and the produced bacterial cells are valid to be used as a potential 
probiotic candidate for further study ex vivo or in vivo in future.  
To study the efficacy of R. aeria as a probiotic for elimination of gliadin immune epitopes, 
it is important to know the effective dosage of R. aeria. Our data showed the optimal ratio of R. 
aeria to gliadin is OD620=1 to 250 ug/ml gliadin. This data can be a good reference for ex vivo and 
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in vitro test. For ex vivo study by using TIM-1 model (Mitea et al., 2008), the amount of food is 
70 g bread, which contains 5 g gluten, indicting 2.5 g gliadin. According to our result, 250 µg/ml 
gliadin was degraded in an OD=1. Therefore, OD=10,000 will be needed for the future TIM-1 
experiment. 
Nowadays, there are some probiotics in the market, especially there is one specific for CD, 
the CeliAct (CeliAct). It is composed of multivitamin including vitamin A, C, D, E, K, etc., and 
mineral complex; probiotic defense complex including Lactospore complex, Lactobacillus 
acidophilus complex, and Bifidobacterium lactis complex; and digestive enzyme support complex 
including lipase complex, Amylase complex, peptidase complex etc. All these complex have to 
pass the generally recognized as safe (GRAS). With the support of the future in vitro and in vivo 
experiments, R. aeria enzyme is potentially to be applied as a probiotic by degrading gluten.  
In summary, full strength BHI broth and 20 to 44 hr cultivation at 37°C are considered as 
optimal cultivation condition to obtain a R. aeria cell culture with high enzyme activity. Starvation 
condition do not enhance enzyme expression.   
  
48 
6. BIBLIOGRAPHY 
 
Adamovic S, Amundsen SS, Lie BA, Gudjonsdottir AH, Ascher H, Ek J et al. (2008). 
Association study of IL2/IL21 and FcgRIIa: significant association with the IL2/IL21 
region in Scandinavian coeliac disease families. Genes and Immunity 9(4):364-367. 
 
Anderson RP, van Heel DA, Tye-Din JA, Jewell DP, Hill AV (2006). Antagonists and non-toxic 
variants of the dominant wheat gliadin T cell epitope in coeliac disease. Gut 55(4):485-
491. 
 
Auricchio S, De Ritis G, De Vincenzi M, Occorsio P, Silano V (1982). Effects of gliadin-derived 
peptides from bread and durum wheats on small intestine cultures from rat fetus and 
coeliac children. Pediatric Research 16(12):1004-1010. 
 
Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M (2008). Commensal bacteria trigger a 
full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor 
T cells. Journal of Leukocyte Biology 84(2):468-476. 
 
Babron MC, Nilsson S, Adamovic S, Naluai AT, Wahlstrom J, Ascher H et al. (2003). Meta and 
pooled analysis of European coeliac disease data. European Journal of Human Genetics 
11(11):828-834. 
 
Bethune MT, Strop P, Tang Y, Sollid LM, Khosla C (2006). Heterologous expression, 
purification, refolding, and structural-functional characterization of EP-B2, a self-
activating barley cysteine endoprotease. Chemistry and Biology 13(6):637-647. 
 
Bettendorf M, Doerr HG, Hauffa BP, Lindberg A, Mehls O, Partsch CJ et al. (2006). Prevalence 
of autoantibodies associated with thyroid and celiac disease in Ullrich-Turner syndrome 
in relation to adult height after growth hormone treatment. Journal of Pediatric 
Endocrinology and Metabolism 19(2):149-154. 
 
Biagi F, Ellis HJ, Parnell ND, Shidrawi RG, Thomas PD, O'Reilly N et al. (1999). A non-toxic 
analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation? 
Alimentary Pharmacology and Therapeutics 13(7):945-950. 
 
Caminero A, Herran AR, Nistal E, Perez-Andres J, Vaquero L, Vivas S et al. (2014). Diversity 
of the cultivable human gut microbiome involved in gluten metabolism: isolation of 
microorganisms with potential interest for coeliac disease. FEMS Microbiology Ecology 
88(2):309-319. 
 
Campieri M, Gionchetti P (1999). Probiotics in inflammatory bowel disease: new insight to 
pathogenesis or a possible therapeutic alternative? Gastroenterology 116(5):1246-1249. 
 
49 
Cerf-Bensussan N, Matysiak-Budnik T, Cellier C, Heyman M (2007). Oral proteases: a new 
approach to managing coeliac disease. Gut 56(2):157-160. 
 
Chen L, Huang L, Min D, Phillips A, Wang S, Madgwick PJ et al. (2012). Development and 
characterization of a new TILLING population of common bread wheat (Triticum 
aestivum L.). PloS One 7(7):e41570. 
 
Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P et al. (2005). Chemistry and biology of 
dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. 
Chemistry and Biology 12(4):469-475. 
 
Collado MC, Calabuig M, Sanz Y (2007). Differences between the fecal microbiota of coeliac 
infants and healthy controls. Curr Issues Intest Microbiol 8(1):9-14. 
 
Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2008). Imbalances in faecal and 
duodenal Bifidobacterium species composition in active and non-active coeliac disease. 
BMC Microbiology 8(232. 
 
Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2009). Specific duodenal and 
faecal bacterial groups associated with paediatric coeliac disease. Journal of Clinical 
Pathology 62(3):264-269. 
 
Cornell HJ, Macrae FA, Melny J, Pizzey CJ, Cook F, Mason S et al. (2005). Enzyme therapy for 
management of coeliac disease. Scandinavian Journal of Gastroenterology 40(11):1304-
1312. 
 
D'Amico MA, Holmes J, Stavropoulos SN, Frederick M, Levy J, DeFelice AR et al. (2005). 
Presentation of pediatric celiac disease in the United States: prominent effect of 
breastfeeding. Clinical Pediatrics 44(3):249-258. 
 
De Angelis M, Rizzello CG, Fasano A, Clemente MG, De Simone C, Silano M et al. (2006). 
VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides 
responsible for Celiac Sprue. Biochimica et Biophysica Acta 1762(1):80-93. 
 
de Macedo P, Marrano C, Keillor JW (2002). Synthesis of dipeptide-bound epoxides and 
alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors. 
Bioorganic and Medicinal Chemistry 10(2):355-360. 
 
De Vincenzi M, Dessi MR, Giovannini C, Maialetti F, Mancini E (1995). Agglutinating activity 
of wheat gliadin peptide fractions in coeliac disease. Toxicology 96(1):29-35. 
 
De Vincenzi M, Luchetti R, Giovannini C, Pogna NE, Saponaro C, Galterio G et al. (1996). In 
vitro toxicity testing of alcohol-soluble proteins from diploid wheat Triticum 
monococcum in celiac disease. Journal of Biochemical Toxicology 11(6):313-318. 
 
50 
De Vincenzi M, Gasbarrini G, Silano V (1997). A small peptide from durum wheat gliadin 
prevents cell agglutination induced by prolamin-peptides toxic in coeliac disease. 
Toxicology 120(3):207-213. 
 
De Vincenzi M, Stammati A, Luchetti R, Silano M, Gasbarrini G, Silano V (1998). Structural 
specificities and significance for coeliac disease of wheat gliadin peptides able to 
agglutinate or to prevent agglutination of K562(S) cells. Toxicology 127(1-3):97-106. 
 
Dema B, Martinez A, Fernandez-Arquero M, Maluenda C, Polanco I, Figueredo MA et al. 
(2009). The IL6-174G/C polymorphism is associated with celiac disease susceptibility in 
girls. Human Immunology 70(3):191-194. 
 
Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH et al. (2010). The human oral 
microbiome. Journal of Bacteriology 192(19):5002-5017. 
 
Di Cagno R, De Angelis M, Lavermicocca P, De Vincenzi M, Giovannini C, Faccia M et al. 
(2002). Proteolysis by sourdough lactic acid bacteria: effects on wheat flour protein 
fractions and gliadin peptides involved in human cereal intolerance. Applied and 
Environmental Microbiology 68(2):623-633. 
 
Di Sabatino A, Corazza GR (2009). Coeliac disease. Lancet 373(9673):1480-1493. 
 
Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S 
(1998). CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. 
Gut 43(2):187-189. 
 
Edens L, Dekker P, van der Hoeven R, Deen F, de Roos A, Floris R (2005). Extracellular prolyl 
endoprotease from Aspergillus niger and its use in the debittering of protein hydrolysates. 
Journal of Agricultural and Food Chemistry 53(20):7950-7957. 
 
Elliott DE, Summers RW, Weinstock JV (2007). Helminths as governors of immune-mediated 
inflammation. International Journal for Parasitology 37(5):457-464. 
 
Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S et al. (2003). Prevalence of celiac 
disease in at-risk and not-at-risk groups in the United States: a large multicenter study. 
Archives of Internal Medicine 163(3):286-292. 
 
Fernandez-Feo M, Wei G, Blumenkranz G, Dewhirst FE, Schuppan D, Oppenheim FG et al. 
(2013). The cultivable human oral gluten-degrading microbiome and its potential 
implications in coeliac disease and gluten sensitivity. Clinical Microbiology and Infection 
19(9):E386-394. 
 
Fulop V, Szeltner Z, Polgar L (2000). Catalysis of serine oligopeptidases is controlled by a 
gating filter mechanism. EMBO Rep 1(3):277-281. 
 
51 
Garner CP, Murray JA, Ding YC, Tien Z, van Heel DA, Neuhausen SL (2009). Replication of 
celiac disease UK genome-wide association study results in a US population. Human 
Molecular Genetics 18(21):4219-4225. 
 
Gass J, Vora H, Bethune MT, Gray GM, Khosla C (2006). Effect of barley endoprotease EP-B2 
on gluten digestion in the intact rat. Journal of Pharmacology and Experimental 
Therapeutics 318(3):1178-1186. 
 
Gass J, Bethune MT, Siegel M, Spencer A, Khosla C (2007). Combination enzyme therapy for 
gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 
133(2):472-480. 
 
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G et al. (2000). Oral 
bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-
blind, placebo-controlled trial. Gastroenterology 119(2):305-309. 
 
Giovannini C, Sanchez M, Straface E, Scazzocchio B, Silano M, De Vincenzi M (2000). 
Induction of apoptosis in caco-2 cells by wheat gliadin peptides. Toxicology 145(1):63-
71. 
 
Goh C, Banerjee K (2007). Prevalence of coeliac disease in children and adolescents with type 1 
diabetes mellitus in a clinic based population. Postgraduate Medical Journal 
83(976):132-136. 
 
Greco L, Corazza G, Babron MC, Clot F, Fulchignoni-Lataud MC, Percopo S et al. (1998). 
Genome search in celiac disease. American Journal of Human Genetics 62(3):669-675. 
 
Greco L, Romino R, Coto I, Di Cosmo N, Percopo S, Maglio M et al. (2002). The first large 
population based twin study of coeliac disease. Gut 50(5):624-628. 
 
Green PH, Jabri B (2003). Coeliac disease. Lancet 362(9381):383-391. 
 
Green PH (2005). The many faces of celiac disease: clinical presentation of celiac disease in the 
adult population. Gastroenterology 128(4 Suppl 1):S74-78. 
 
Green PH, Cellier C (2007). Celiac disease. New England Journal of Medicine 357(17):1731-
1743. 
 
Haimila K, Einarsdottir E, de Kauwe A, Koskinen LL, Pan-Hammarstrom Q, Kaartinen T et al. 
(2009). The shared CTLA4-ICOS risk locus in celiac disease, IgA deficiency and 
common variable immunodeficiency. Genes and Immunity 10(2):151-161. 
 
Hausch F, Shan L, Santiago NA, Gray GM, Khosla C (2002). Intestinal digestive resistance of 
immunodominant gliadin peptides. American Journal of Physiology: Gastrointestinal 
and Liver Physiology 283(4):G996-G1003. 
 
52 
Hausch F, Halttunen T, Maki M, Khosla C (2003). Design, synthesis, and evaluation of gluten 
peptide analogs as selective inhibitors of human tissue transglutaminase. Chemistry and 
Biology 10(3):225-231. 
 
Helmerhorst EJ, Zamakhchari M, Schuppan D, Oppenheim FG (2010). Discovery of a novel and 
rich source of gluten-degrading microbial enzymes in the oral cavity. PloS One 
5(10):e13264. 
 
Henderson KN, Tye-Din JA, Reid HH, Chen Z, Borg NA, Beissbarth T et al. (2007). A 
structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac 
disease. Immunity 27(1):23-34. 
 
Jacobsen JV, Varner JE (1967). Gibberellic Acid-induced synthesis of protease by isolated 
aleurone layers of barley. Plant Physiology 42(11):1596-1600. 
 
Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJ (2005). Mechanism for the inhibition 
of transglutaminase 2 by cystamine. Biochemical Pharmacology 69(6):961-970. 
 
Kagnoff MF (2005). Overview and pathogenesis of celiac disease. Gastroenterology 128(4 
Suppl 1):S10-18. 
 
Kapoerchan VV, Wiesner M, Overhand M, van der Marel GA, Koning F, Overkleeft HS (2008). 
Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses 
associated with celiac disease. Bioorganic and Medicinal Chemistry 16(4):2053-2062. 
 
Kaur IP, Chopra K, Saini A (2002). Probiotics: potential pharmaceutical applications. European 
Journal of Pharmaceutical Sciences 15(1):1-9. 
 
Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004). Structural basis for HLA-DQ2-
mediated presentation of gluten epitopes in celiac disease. Proceedings of the National 
Academy of Sciences of the United States of America 101(12):4175-4179. 
 
Koehler SM, Ho TH (1990). Hormonal regulation, processing, and secretion of cysteine 
proteinases in barley aleurone layers. Plant Cell 2(8):769-783. 
 
Koning F, Vader W (2003). Gluten peptides and celiac disease. Science 299(5606):513-515; 
author reply 513-515. 
 
Koskinen LL, Einarsdottir E, Dukes E, Heap GA, Dubois P, Korponay-Szabo IR et al. (2009). 
Association study of the IL18RAP locus in three European populations with coeliac 
disease. Human Molecular Genetics 18(6):1148-1155. 
 
Krainick HG, Mohn G (1959). [Further investigations on the toxic effect of wheat flour in celiac 
disease. 2. Effect of enzymatic by-products of gliadin]. Helvetica Paediatrica Acta 
14(2):124-140. 
 
53 
Lai TS, Slaughter TF, Peoples KA, Hettasch JM, Greenberg CS (1998). Regulation of human 
tissue transglutaminase function by magnesium-nucleotide complexes. Identification of 
distinct binding sites for Mg-GTP and Mg-ATP. Journal of Biological Chemistry 
273(3):1776-1781. 
 
Li Y, Kawamura Y, Fujiwara N, Naka T, Liu H, Huang X et al. (2004). Rothia aeria sp. nov., 
Rhodococcus baikonurensis sp. nov. and Arthrobacter russicus sp. nov., isolated from air 
in the Russian space laboratory Mir. International Journal of Systematic and 
Evolutionary Microbiology 54(Pt 3):827-835. 
 
Liu J, Juo SH, Holopainen P, Terwilliger J, Tong X, Grunn A et al. (2002). Genomewide linkage 
analysis of celiac disease in Finnish families. American Journal of Human Genetics 
70(1):51-59. 
 
Lu R, Wang W, Uzzau S, Vigorito R, Zielke HR, Fasano A (2000). Affinity purification and 
partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human 
brain. Journal of Neurochemistry 74(1):320-326. 
 
Marsh MN (1992). Gluten, major histocompatibility complex, and the small intestine. A 
molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac 
sprue'). Gastroenterology 102(1):330-354. 
 
Marti T, Molberg O, Li Q, Gray GM, Khosla C, Sollid LM (2005). Prolyl endopeptidase-
mediated destruction of T cell epitopes in whole gluten: chemical and immunological 
characterization. Journal of Pharmacology and Experimental Therapeutics 312(1):19-26. 
 
Matysiak-Budnik T, Candalh C, Cellier C, Dugave C, Namane A, Vidal-Martinez T et al. 
(2005). Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin 
peptides in celiac disease. Gastroenterology 129(3):786-796. 
 
McCallum CM, Comai L, Greene EA, Henikoff S (2000). Targeting induced local lesions IN 
genomes (TILLING) for plant functional genomics. Plant Physiology 123(2):439-442. 
 
McIntire RH, Sifers T, Platt JS, Ganacias KG, Langat DK, Hunt JS (2008). Novel HLA-G-
binding leukocyte immunoglobulin-like receptor (LILR) expression patterns in human 
placentas and umbilical cords. Placenta 29(7):631-638. 
 
Medina M, Izquierdo E, Ennahar S, Sanz Y (2007). Differential immunomodulatory properties 
of Bifidobacterium logum strains: relevance to probiotic selection and clinical 
applications. Clinical and Experimental Immunology 150(3):531-538. 
 
Medina M, De Palma G, Ribes-Koninckx C, Calabuig M, Sanz Y (2008). Bifidobacterium 
strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal 
microbiota of coeliac patients. J Inflamm (Lond) 5(19. 
 
54 
Mikkonen A, Porali I, Cercos M, Ho TH (1996). A major cysteine proteinase, EPB, in 
germinating barley seeds: structure of two intronless genes and regulation of expression. 
Plant Molecular Biology 31(2):239-254. 
 
Mitea C, Havenaar R, Drijfhout JW, Edens L, Dekking L, Koning F (2008). Efficient 
degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications 
for coeliac disease. Gut 57(1):25-32. 
 
Mohamed BM, Feighery C, Kelly J, Coates C, O'Shea U, Barnes L et al. (2006). Increased 
protein expression of matrix metalloproteinases -1, -3, and -9 and TIMP-1 in patients 
with gluten-sensitive enteropathy. Digestive Diseases and Sciences 51(10):1862-1868. 
 
Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, Madsen L et al. (1998). Tissue 
transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived 
T cells in celiac disease. Nature Medicine 4(6):713-717. 
 
Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E et al. 
(2005). Myosin IXB variant increases the risk of celiac disease and points toward a 
primary intestinal barrier defect. Nature Genetics 37(12):1341-1344. 
 
Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y (2007). Imbalance in the composition 
of the duodenal microbiota of children with coeliac disease. Journal of Medical 
Microbiology 56(Pt 12):1669-1674. 
 
Naluai AT, Nilsson S, Samuelsson L, Gudjonsdottir AH, Ascher H, Ek J et al. (2000). The 
CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease 
in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory 
disorders. Tissue Antigens 56(4):350-355. 
 
Naluai AT, Nilsson S, Gudjonsdottir AH, Louka AS, Ascher H, Ek J et al. (2001). Genome-wide 
linkage analysis of Scandinavian affected sib-pairs supports presence of susceptibility 
loci for celiac disease on chromosomes 5 and 11. European Journal of Human Genetics 
9(12):938-944. 
 
Nilsen EM JF, Lundin KE, Johansen FE, Fausa O, Sollid LM, Jahnsen J, Scott H, Brandtzaeg P. 
(1998). Gluten induces an intestinal cytokine response strongly dominated by interferon 
gamma in patients with celiac disease. Gastroenterology 115(3):551-563. 
 
Norris JM, Barriga K, Hoffenberg EJ, Taki I, Miao D, Haas JE et al. (2005). Risk of celiac 
disease autoimmunity and timing of gluten introduction in the diet of infants at increased 
risk of disease. JAMA 293(19):2343-2351. 
 
O'Mahony S, Howdle PD, Losowsky MS (1996). Review article: management of patients with 
non-responsive coeliac disease. Alimentary Pharmacology and Therapeutics 10(5):671-
680. 
 
55 
Ou G, Hedberg M, Horstedt P, Baranov V, Forsberg G, Drobni M et al. (2009). Proximal small 
intestinal microbiota and identification of rod-shaped bacteria associated with childhood 
celiac disease. American Journal of Gastroenterology 104(12):3058-3067. 
 
Ozkan H FM (2001). Genotypic variation in tetraploid wheat affecting homoeologous pairing in 
hybrids with Aegilops peregrina. Genome 44(6):1000-1006. 
 
Pardin C, Roy I, Lubell WD, Keillor JW (2008). Reversible and competitive cinnamoyl triazole 
inhibitors of tissue transglutaminase. Chemical Biology & Drug Design 72(3):189-196. 
 
Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB (2007). The safety, tolerance, 
pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac 
disease subjects: a proof of concept study. Alimentary Pharmacology and Therapeutics 
26(5):757-766. 
 
Pavone P, Nicolini E, Taibi R, Ruggieri M (2007). Rotavirus and celiac disease. American 
Journal of Gastroenterology 102(8):1831. 
 
Piper JL, Gray GM, Khosla C (2004). Effect of prolyl endopeptidase on digestive-resistant 
gliadin peptides in vivo. Journal of Pharmacology and Experimental Therapeutics 
311(1):213-219. 
 
Pyle GG, Paaso B, Anderson BE, Allen DD, Marti T, Li Q et al. (2005). Effect of pretreatment 
of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac 
sprue. Clinical Gastroenterology and Hepatology 3(7):687-694. 
 
Rizzello CG, De Angelis M, Di Cagno R, Camarca A, Silano M, Losito I et al. (2007). Highly 
efficient gluten degradation by lactobacilli and fungal proteases during food processing: 
new perspectives for celiac disease. Applied and Environmental Microbiology 
73(14):4499-4507. 
 
Romanos J, van Diemen CC, Nolte IM, Trynka G, Zhernakova A, Fu J et al. (2009). Analysis of 
HLA and non-HLA alleles can identify individuals at high risk for celiac disease. 
Gastroenterology 137(3):834-840, 840 e831-833. 
 
Rostom A, Murray JA, Kagnoff MF (2006). American Gastroenterological Association (AGA) 
Institute technical review on the diagnosis and management of celiac disease. 
Gastroenterology 131(6):1981-2002. 
 
Schuppan D, Junker Y, Barisani D (2009). Celiac disease: from pathogenesis to novel therapies. 
Gastroenterology 137(6):1912-1933. 
 
Shamaly H, Hartman C, Pollack S, Hujerat M, Katz R, Gideoni O et al. (2007). Tissue 
transglutaminase antibodies are a useful serological marker for the diagnosis of celiac 
disease in patients with Down syndrome. Journal of Pediatric Gastroenterology and 
Nutrition 44(5):583-586. 
56 
 
Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM et al. (2002). Structural basis for 
gluten intolerance in celiac sprue. Science 297(5590):2275-2279. 
 
Shan L, Marti T, Sollid LM, Gray GM, Khosla C (2004). Comparative biochemical analysis of 
three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochemical Journal 
383(Pt 2):311-318. 
 
Siegel M, Bethune MT, Gass J, Ehren J, Xia J, Johannsen A et al. (2006). Rational design of 
combination enzyme therapy for celiac sprue. Chemistry and Biology 13(6):649-658. 
 
Siegel M, Khosla C (2007). Transglutaminase 2 inhibitors and their therapeutic role in disease 
states. Pharmacology and Therapeutics 115(2):232-245. 
 
Silano M, Di Benedetto R, Trecca A, Arrabito G, Leonardi F, De Vincenzi M (2007a). A 
decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from 
activation by gliadin peptides. Pediatric Research 61(1):67-71. 
 
Silano M, Leonardi F, Trecca A, Mancini E, Di Benedetto R, De Vincenzi M (2007b). 
Prevention by a decapeptide from durum wheat of in vitro gliadin peptide-induced 
apoptosis in small-bowel mucosa from coeliac patients. Scandinavian Journal of 
Gastroenterology 42(6):786-787. 
 
Silano M, Di Benedetto R, Maialetti F, De Vincenzi A, Calcaterra R, Trecca A et al. (2008). A 
10-residue peptide from durum wheat promotes a shift from a Th1-type response toward 
a Th2-type response in celiac disease. American Journal of Clinical Nutrition 87(2):415-
423. 
 
Slade AJ, Fuerstenberg SI, Loeffler D, Steine MN, Facciotti D (2005). A reverse genetic, 
nontransgenic approach to wheat crop improvement by TILLING. Nature Biotechnology 
23(1):75-81. 
 
Sollid LM (2000). Molecular basis of celiac disease. Annual Review of Immunology 18(53-81. 
 
Sollid LM (2002). Coeliac disease: dissecting a complex inflammatory disorder. Nature 
Reviews: Immunology 2(9):647-655. 
 
Sollid LM, Lie BA (2005). Celiac disease genetics: current concepts and practical applications. 
Clinical Gastroenterology and Hepatology 3(9):843-851. 
 
Sollid LM, Khosla C (2011). Novel therapies for coeliac disease. Journal of Internal Medicine 
269(6):604-613. 
 
Sparks CA, Jones HD (2009). Biolistics transformation of wheat. Methods in Molecular Biology 
478(71-92. 
 
57 
Sparla F, Falini G, Botticella E, Pirone C, Talamè V, Bovina R et al. (2014). New Starch 
Phenotypes Produced by TILLING in Barley. PloS One 9(10):e107779. 
 
Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L et al. (2006). Rotavirus 
infection frequency and risk of celiac disease autoimmunity in early childhood: a 
longitudinal study. American Journal of Gastroenterology 101(10):2333-2340. 
 
Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, Baak-Pablo R et al. (2006). 
Highly efficient gluten degradation with a newly identified prolyl endoprotease: 
implications for celiac disease. American Journal of Physiology: Gastrointestinal and 
Liver Physiology 291(4):G621-629. 
 
Summers RW, Elliott DE, Urban JF, Jr., Thompson R, Weinstock JV (2005a). Trichuris suis 
therapy in Crohn's disease. Gut 54(1):87-90. 
 
Summers RW, Elliott DE, Urban JF, Jr., Thompson RA, Weinstock JV (2005b). Trichuris suis 
therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 
128(4):825-832. 
 
Tian N, Wei G, Schuppan D, Helmerhorst EJ (2014). Effect of Rothia mucilaginosa enzymes on 
gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac 
disease. American Journal of Physiology: Gastrointestinal and Liver Physiology 
307(8):G769-776. 
 
Tsuzukibashi O, Uchibori S, Kobayashi T, Umezawa K, Mashimo C, Nambu T et al. (2017). 
Isolation and identification methods of Rothia species in oral cavities. Journal of 
Microbiological Methods 134(21-26. 
 
Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI (2007). The human 
microbiome project. Nature 449(7164):804-810. 
 
Uzzau S, Lu R, Wang W, Fiore C, Fasano A (2001). Purification and preliminary 
characterization of the zonula occludens toxin receptor from human (CaCo2) and murine 
(IEC6) intestinal cell lines. FEMS Microbiology Letters 194(1):1-5. 
 
van Belzen MJ, Mulder CJ, Zhernakova A, Pearson PL, Houwen RH, Wijmenga C (2004). 
CTLA4 +49 A/G and CT60 polymorphisms in Dutch coeliac disease patients. European 
Journal of Human Genetics 12(9):782-785. 
 
van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M et al. (2007). A 
genome-wide association study for celiac disease identifies risk variants in the region 
harboring IL2 and IL21. Nature Genetics 39(7):827-829. 
 
Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT et al. (1999). Bovine 
immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising 
activity after passage through the human stomach and small intestine. Gut 44(2):212-217. 
58 
 
Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, Zielke R et al. (2005). Role of the intestinal 
tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-
prone rats. Proceedings of the National Academy of Sciences of the United States of 
America 102(8):2916-2921. 
 
Wei G, Tian N, Valery AC, Zhong Y, Schuppan D, Helmerhorst EJ (2015). Identification of 
Pseudolysin (lasB) as an Aciduric Gluten-Degrading Enzyme with High Therapeutic 
Potential for Celiac Disease. American Journal of Gastroenterology 110(6):899-908. 
 
Wei G, Tian N, Siezen R, Schuppan D, Helmerhorst EJ (2016). Identification of food-grade 
subtilisins as gluten-degrading enzymes to treat celiac disease. American Journal of 
Physiology - Gastrointestinal and Liver Physiology 311(3):G571-G580. 
 
Woolley N, Holopainen P, Bourgain C, Mustalahti K, Collin P, Maki M et al. (2002). CD80 (B7-
1) and CD86 (B7-2) genes and genetic susceptibility to coeliac disease. European 
Journal of Immunogenetics 29(4):331-333. 
 
Wu H, Doherty A, Jones HD (2009). Agrobacterium-mediated transformation of bread and 
durum wheat using freshly isolated immature embryos. Methods in Molecular Biology 
478(93-103. 
 
Xia J, Siegel M, Bergseng E, Sollid LM, Khosla C (2006). Inhibition of HLA-DQ2-mediated 
antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-
gliadin. Journal of the American Chemical Society 128(6):1859-1867. 
 
Yokoyama K, Nio N, Kikuchi Y (2004). Properties and applications of microbial 
transglutaminase. Applied Microbiology and Biotechnology 64(4):447-454. 
 
Zamakhchari M, Wei G, Dewhirst F, Lee J, Schuppan D, Oppenheim FG et al. (2011). 
Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper 
gastro-intestinal tract. PloS One 6(9):e24455. 
 
Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S et al. (2006). In celiac disease, a 
subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces 
activation of monocytes. PLoS Medicine 3(9):e358. 
 
 
  
59 
 
CURRICULUM VITAE 
 
60 
